1-3 of 3
Robert Arceci, MD
Close
Sort by
Journal Articles

Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.

Patrick Brown, MD, Emily McIntyre, Rachel Rau, MD, Todd A. Alonzo, PhD, Robert Gerbing, MA, Soheil Meshinchi, MD PhD, Norman Lacayo, MD, Myron Chang, PhD, Robert Arceci, MD PhD, Donald Small, MD PhD
Journal: Blood
Blood (2006) 108 (11): 221.
https://doi.org/10.1182/blood.V108.11.221.221
Published: 2006
Journal Articles

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred Behm, MD, Myron Chang, Robert Arceci, MD
Journal: Blood
Blood (2006) 108 (11): 3677.
https://doi.org/10.1182/blood.V108.11.3677.3677
Published: 2006
Journal Articles

Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.

Alan S. Gamis, MD, Todd A. Alonzo, PhD, Joanne M. Hilden, MD, Robert B. Gerbing, MA, Thomas W. Loew, MD, Lois Hathaway, CCRP, Loris McGavran, PhD, Dorothy Barnard, MD, Jeffrey W. Taub, MD, Yaddanapudi Ravindranath, MD, Franklin O. Smith, MD, Robert Arceci, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 15.
https://doi.org/10.1182/blood.V108.11.15.15
Published: 2006